All Experts


Meet the Expert: Matthew R. Smith, MD, PhD
Director of Research, Genitourinary Unit of Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, USA

Dr. Matthew R. Smith is Associate Professor of Medicine at Harvard Medical School and the Director of Genitourinary Medical Oncology at Massachusetts General Hospital Cancer Center in Boston.

He earned his medical degree at Duke University, and completed his training in internal medicine at Brigham and Women's Hospital and in medical oncology at Dana-Farber Cancer Institute.

Dr. Smith is the recipient of numerous awards, including a Midcareer Investigator Award from the National Institutes of Health and competitive research awards from the Prostate Cancer Foundation and Lance Armstrong Foundation. He has been published in a number of journals, including Journal of Clinical Oncology, Cancer, Urology, Journal of Urology and The New England Journal of Medicine.

Clinical Interests:

• Bone metastases
• Hormone therapy
• Cancer survivorship, including:
  • osteoporosis
  • obesity
  • diabetes
  • cardiovascular disease

Professional Memberships:

• American Society of Clinical Oncology
• American Urologic Association
• American Society for Bone and Mineral Research

Selected Publications:

• Denosumab in men receiving androgen-deprivation therapy for prostate cancer


• NCCN Task Force Report: Bone Health in Cancer Care


• Phase II study of sunitinib in men with advanced prostate cancer


• Metabolic complications of androgen deprivation therapy for prostate cancer


• Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31


• Androgen Deprivation Therapy for the Treatment of Prostate Cancer: Consider Both Benefits and Risks


• Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference


• Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors


• Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database


• Osteoclast targeted therapy for prostate cancer: bisphosphonates and beyond


• Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions


• Management of complications of prostate cancer treatment


• Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study


• Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome


• Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity


• Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer


• Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02


• Estrogenic side effects of androgen deprivation therapy


• Use of androgen deprivation therapy for metastatic prostate cancer in older men


• Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study


• Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31


• Androgen deprivation therapy for prostate cancer: new concepts and concerns


• Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer


• Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapy


• Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer


• Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer


• Treatment-related osteoporosis in men with prostate cancer


• Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference


• Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer


• Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy


• Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer


• Markers of bone metabolism in prostate cancer


• Therapy Insight: osteoporosis during hormone therapy for prostate cancer


• Insulin sensitivity during combined androgen blockade for prostate cancer


• Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer


• Bisphosphonates for treatment and prevention of bone metastases


• Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence


• Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma


• Future therapies in hormone-refractory prostate cancer


• Osteoporosis and obesity in men receiving hormone therapy for prostate cancer


• Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy


• Osteoclast-targeted therapy for prostate cancer


• Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial


• Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy


• Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition


• The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy


• Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate


• Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer


• Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer


• Changes in body composition during hormonal therapy for prostate cancer


• Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies


• Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer


• Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer


• Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance


• Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up


• Management of treatment-related osteoporosis in men with prostate cancer


• The role of bisphosphonates in the management of metastatic prostate cancer


• Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer


• Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer


• Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma


• Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study


• Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer


• Selective aromatase inhibition for patients with androgen-independent prostate carcinoma


• Osteoporosis during androgen deprivation therapy for prostate cancer